BACKGROUND: M2BPGi is a novel serum glycobiomarker of liver fibrosis. In this study, we aimed to evaluate the efficacy of M2BPGi for predicting liver fibrosis and disease progression in Chinese hepatitis B virus (HBV) infected patients. METHODS: We enrolled 228 HBV infected patients with different status of liver fibrosis diagnosed using FibroScan. We analyzed the diagnostic accuracy of M2BPGi, and compared it with AST-to-platelet ratio (APRI), FIB-4 index, AST to ALT ratio (AAR), and RDW to platelet ratio (RPR). We performed receiver operating characteristics curve (ROC) to evaluate the diagnostic performance of M2BPGi for significant fibrosis and cirrhosis. RESULTS: Median M2BPGi values in each fibrosis stage were: 0.88 cut-off index (COI) in F0-1, 1.165 in F2-3, and 1.92 in F4 (P<.01), respectively. For F≥2, the sensitivity, specificity, accuracy of M2BPGi were 72.28%, 73.23%, 66.67%, while 55.07%, 93.71%, 82.02% for F≥4. For predicting significant fibrosis (≥F2), M2BPGi showed comparable performance to FIB4 index (P<.01), APRI (P<.01) and RPR (P<.01) with area under the ROC curve (AUC) of 0.788. M2BPGi was superior to other surrogate markers for diagnosing cirrhosis (F4) with the highest AUC of 0.811 (P<.01). CONCLUSIONS: M2BPGi levels increased with the progression of liver fibrosis in HBV infected patients. M2BPGi can be served as a potential glycobiomarker to assess the stage of liver fibrosis, especially for the diagnosis of cirrhosis.
BACKGROUND: M2BPGi is a novel serum glycobiomarker of liver fibrosis. In this study, we aimed to evaluate the efficacy of M2BPGi for predicting liver fibrosis and disease progression in Chinese hepatitis B virus (HBV) infectedpatients. METHODS: We enrolled 228 HBV infectedpatients with different status of liver fibrosis diagnosed using FibroScan. We analyzed the diagnostic accuracy of M2BPGi, and compared it with AST-to-platelet ratio (APRI), FIB-4 index, AST to ALT ratio (AAR), and RDW to platelet ratio (RPR). We performed receiver operating characteristics curve (ROC) to evaluate the diagnostic performance of M2BPGi for significant fibrosis and cirrhosis. RESULTS: Median M2BPGi values in each fibrosis stage were: 0.88 cut-off index (COI) in F0-1, 1.165 in F2-3, and 1.92 in F4 (P<.01), respectively. For F≥2, the sensitivity, specificity, accuracy of M2BPGi were 72.28%, 73.23%, 66.67%, while 55.07%, 93.71%, 82.02% for F≥4. For predicting significant fibrosis (≥F2), M2BPGi showed comparable performance to FIB4 index (P<.01), APRI (P<.01) and RPR (P<.01) with area under the ROC curve (AUC) of 0.788. M2BPGi was superior to other surrogate markers for diagnosing cirrhosis (F4) with the highest AUC of 0.811 (P<.01). CONCLUSIONS: M2BPGi levels increased with the progression of liver fibrosis in HBV infectedpatients. M2BPGi can be served as a potential glycobiomarker to assess the stage of liver fibrosis, especially for the diagnosis of cirrhosis.
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425